Ciprofloxacin

C difficile risk
High
Oral Bioavailability
Excellent
Cost
IV:$ PO:¢

Dosing

CrCl >50 mL/minCrCl ≤50 mL/min250-750mg PO Q12h, or 400mg IV Q8-12h250-500mg IM Q12, or 500mg ER Q12h, or 200-400mg PO Q18-24h

500mg PO/ 400mg IV Q24h (doses given on HD days should be given after HD)

200-400mg IV Q12h

PO: 500-750mg po q12h

IV: 400mg IV q8-12h

General Information

Pseudomonal and other gram negative infections of urinary tract, bone/joint, abdomen and other sites

Monitor QTc in patients with increased risk

  • QTc prolongation

  • Dysglycemia

  • Tendinopathy and rupture

  • GI upset

  • Rash

  • Retinal detachment

  • CNS toxicity including confusion, psychosis

  • Weakness exacerbation in myasthenia gravis

CYP1A2 inhibitor - Multiple interactions possible.

QTc prolongation - Increased risk with other agents that prolong QTc.

Divalent & trivalent cations including Al, Ca, Fe, Mg (antacids, dairy products, iron supplements, some enteral feeds) - Decreased absorption

Cyclosporine - Increased levels of cyclosporine

Warfarin - Increased INR Methadone - Lowered seizure threshold

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 4 hours

Biliary penetration: Therapeutic

CSF penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic